Clinical Trial Update: A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study of TAK-771 in Japanese participants with primary immunodeficiency disease has completed, providing safety data from extended foll…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Disease

Drugs mentioned

• TAK-771

Snippet

Sponsor: Takeda | Conditions: Primary Immunodeficiency Diseases (PID) | Phase 3 | Status: COMPLETED